NASDAQ : MEDP
-$4.82 (-0.8%)
NASDAQ
August James Troendle
Medical - Diagnostics & Research
Healthcare
MEDP
6200
US
USD
0.28
0.73
0.73
0.35
0.00
$2.53B
6.17
39.21
22.46
27.00
$15.28
$451.12M
17.67%
21.53%
110.15%
23.89%
34.56
1.34
1.34
$600.00
$665.00
$484.00
3/5
19 Analysts
0.17%
8.12
7/9
-$385.14M
$2.06B
$1.62B
$588M
$16.92B
6.08
28.10
0.73
110.15%
77.00%
2.87%
4.42%
$77.38
51 days
| Name | Title |
|---|---|
| John T. Wynne | Chief Business Officer |
| Stephen Ewald | Chief Compliance Officer, General Counsel & Corporate Secretary |
| Susan E. Burwig | Executive Vice President of Operations |
| Kevin Brady | Chief Financial Officer & Treasurer |
| Lauren Morris | Associate Director of Investors Relations |
| Jesse J. Geiger | President |
| August James Troendle | CEO, President & Chairman |
| Brad W. Hansman | Executive Vice President of Operations |
| Brandon Ebken | Chief Information Officer |
| Todd Meyers | Vice President of Business Development & Marketing |
| Weimin Gai | Senior Vice President of Biometrics |
| Gina Leisring | Senior Vice President of Clinical Monitoring |
| Reinilde Heyrman | Chief Medical Officer of Medical Department |
No votes yet today — be the first to share your view!
About Medpace Holdings, Inc. (NASDAQ:MEDP) Stock
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermor ... e, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?
2026-07-24 10:16:20
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Medpace Soars After Q2 Beat, Strong Backlog Fuels Higher 2026 Outlook
2026-07-23 14:15:41
Medpace Holdings Inc. (NASDAQ:MEDP) stock is trading higher on Thursday on better-than-expected second-quarter financial results and raised its fiscal 2026 guidance.
Medpace: 'Buy' On Financial Metric Improvements And Solid Q2 2026 Earnings
2026-07-23 12:47:00
Medpace Holdings remains a "Buy" as Q2 2026 showed broad metric improvement and an inflection point in growth trajectory. The company's net book-to-Bill ratio rebounded to 1.13x, and backlog conversion rate rose to 24.1%, signaling strong future revenue visibility. Revenue grew 17.2% YoY to $707.3M, with EPS of $4.25 beating expectations; full-year 2026 guidance was raised to $2.805B–$2.885B.
Medpace Holdings, Inc. (MEDP) Q2 2026 Earnings Call Transcript
2026-07-23 12:20:29
Medpace Holdings, Inc. (MEDP) Q2 2026 Earnings Call Transcript
Medpace Q2 Earnings Call Highlights
2026-07-23 11:08:01
Medpace NASDAQ: MEDP reported double-digit growth in second-quarter revenue and earnings, while management described the business environment as strong and said lower cancellations helped drive record net bookings.
Medpace (MEDP) Beats Q2 Earnings and Revenue Estimates
2026-07-22 18:56:16
Medpace (MEDP) came out with quarterly earnings of $4.25 per share, beating the Zacks Consensus Estimate of $4.08 per share. This compares to earnings of $3.1 per share a year ago.
Medpace Notches A Big Bookings Beat, And Reverses Its First-Quarter Malaise
2026-07-22 17:46:27
Medpace stock surged by double digits late Wednesday helped by a big bookings beat.
Medpace Holdings, Inc. Reports Second Quarter 2026 Results
2026-07-22 16:15:00
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Results Revenue for the three months ended June 30, 2026 increased 17.2% to $707.3 million, compared to $603.3 million for the comparable prior-year period. On a constant currency basis, revenue for the second quarter of 2026 increased 17.2% compared to the second quarter of 2025. Backlog as of June 30, 2026 in.
Frequently Asked Questions
What is the current Medpace Holdings, Inc. (MEDP) stock price?
Medpace Holdings, Inc.(NASDAQ:MEDP) stock price is $601.0008 in the last trading session. During the trading session, MEDP stock reached the peak price of $677.9 while $373 was the lowest point it dropped to. The percentage change in MEDP stock occurred in the recent session was --0.8% while the dollar amount for the price change in MEDP stock was -$4.82.
MEDP's industry and sector of operation?
The NASDAQ listed MEDP is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
Who are the executives of MEDP?
John T. Wynne
| Chief Business Officer
Stephen Ewald
| Chief Compliance Officer, General Counsel & Corporate Secretary
Susan E. Burwig
| Executive Vice President of Operations
Kevin Brady
| Chief Financial Officer & Treasurer
Lauren Morris
| Associate Director of Investors Relations
How many employees does MEDP have?
Number of MEDP employees currently stands at 6200. MEDP operates from 5375 Medpace Way, Cincinnati, OH 45227, US.
Link for MEDP official website?
Official Website of MEDP is: https://www.medpace.com
How do I contact MEDP?
MEDP could be contacted at phone #513 579 9911 and can also be accessed through its website. MEDP operates from 5375 Medpace Way, Cincinnati, OH 45227, US.
How many shares of MEDP are traded daily?
The average number of MEDP shares traded daily for last 3 months was 345.88K.
What is the market cap of MEDP currently?
The market value of MEDP currently stands at $17.16B with its latest stock price at $601.0008